Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

BeOne Medicines’ Novel BCL2 inhibitor, sonrotoclax, achieves first-in-world approval in R/R MCL and R/R CLL/SLL: San Carlos, California Thursday, January 8, 2026, 13:00 Hrs [IST ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed ...

Dr Haumschild drives a discussion surrounding the role of bruton kinase inhibitors for treating CLL and SLL. This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval ...

After reading a book about how Imbruvica was revolutionized for SLL and CLL, I now have a greater appreciation for the drugs I receive. As a patient diagnosed with small lymphocytic lymphoma (SLL), my ...

The FDA granted accelerated approval to lisocabtagene maraleucel (liso-cel, Breyanzi) for pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), drugmaker Bristol Myers ...